Efficacy and Safety of Cipros 20 Association on Dyslipidemia Treatment

• Status: Recruiting
• Trial end date: 2022-12-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy of Cipros 20 association in the treatment of dyslipidemia treatment.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: EMS
• Treatments: Ciprofloxacin; Rosuvastatin Calcium

Criteria

Inclusion Criteria:

• Participants of both sexes, aged 18 years or more;

• Participants with the diagnosed of dyslipidemia and with high or very high cardiovascular risk, according to the Brazillian Guidelines on Dyslipidemia and Prevention of Atherosclerosis;

• Signed consent.

Exclusion Criteria:

• Using medications that may interfere with the metabolism or serum levels of triglycerides;

• Any clinical and laboratory findings that, in the judgment of the investigator, may interfere with the safety of research participants;

• Presence of concomitant cardiovascular disease, renal failure and hepatic failure;

• Decompensated diabetes;

• Current smoking;

• History hypersensitivity to the active ingredients used in the study;

• Pregnancy or risk of pregnancy and lactating patients;

• History of alcohol abuse or illicit drug use;

• Participation in clinical trial in the year prior to this study.